Treatment of Bacterial Meningitis

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Therapeutic strategies for acute bacterial meningitis are evolving due to changing antimicrobial susceptibility patterns of key pathogens.
• Emergence of resistant strains, particularly Streptococcus pneumoniae and Neisseria meningitidis, challenges standard treatment protocols.
• Gram-negative bacilli causing meningitis also show increasing resistance to third-generation cephalosporins.

Purpose of the Study:

• To review current therapeutic approaches for acute bacterial meningitis in light of evolving antimicrobial resistance.
• To provide updated recommendations for empiric therapy based on pathogen susceptibility.
• To highlight the critical need for ongoing surveillance of meningeal pathogen susceptibility.

Main Methods:

• Review of recent literature and clinical guidelines concerning bacterial meningitis treatment.
• Analysis of in vitro antimicrobial susceptibility data for common meningeal pathogens.
• Evaluation of alternative antimicrobial agents for resistant infections.

Main Results:

• Vancomycin combined with a third-generation cephalosporin is recommended for empiric treatment of Streptococcus pneumoniae meningitis due to penicillin and cephalosporin resistance.
• While Neisseria meningitidis resistance to penicillin is noted, standard therapy remains effective in most cases.
• Carbapenems and fluoroquinolones show promise as alternative agents for meningitis caused by gram-negative bacilli resistant to third-generation cephalosporins.

Conclusions:

• Current treatment guidelines for bacterial meningitis must adapt to increasing antimicrobial resistance.
• Continuous surveillance of in vitro antimicrobial susceptibility is crucial for refining future treatment recommendations.
• Combination therapy and alternative agents are essential for managing resistant bacterial meningitis cases.